Concepts (257)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurofibromatosis 1 | 12 | 2021 | 36 | 1.800 |
Why?
|
| Neurofibromatosis 2 | 4 | 2023 | 11 | 0.620 |
Why?
|
| Neurofibromatoses | 4 | 2021 | 9 | 0.520 |
Why?
|
| Fatty Acids | 5 | 1998 | 130 | 0.460 |
Why?
|
| Reye Syndrome | 8 | 1991 | 22 | 0.450 |
Why?
|
| Neuroma, Acoustic | 2 | 2023 | 20 | 0.420 |
Why?
|
| Dicarboxylic Acids | 7 | 1991 | 22 | 0.390 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 1169 | 0.360 |
Why?
|
| Neurofibroma, Plexiform | 3 | 2021 | 10 | 0.360 |
Why?
|
| Neurilemmoma | 3 | 2021 | 34 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2021 | 101 | 0.290 |
Why?
|
| Nervous System Neoplasms | 1 | 2006 | 11 | 0.280 |
Why?
|
| Child | 20 | 2023 | 6927 | 0.270 |
Why?
|
| Pain Measurement | 2 | 2016 | 321 | 0.230 |
Why?
|
| Hearing Loss | 1 | 2023 | 56 | 0.220 |
Why?
|
| Bevacizumab | 2 | 2023 | 281 | 0.220 |
Why?
|
| Self Report | 2 | 2021 | 288 | 0.210 |
Why?
|
| Aspirin | 4 | 1993 | 156 | 0.200 |
Why?
|
| Quality of Life | 5 | 2023 | 1585 | 0.200 |
Why?
|
| Diphenylamine | 1 | 2021 | 4 | 0.200 |
Why?
|
| Skin Neoplasms | 3 | 2021 | 546 | 0.200 |
Why?
|
| Lovastatin | 2 | 2019 | 29 | 0.190 |
Why?
|
| Adolescent | 14 | 2021 | 8981 | 0.190 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2019 | 183 | 0.190 |
Why?
|
| Child, Preschool | 11 | 2020 | 3612 | 0.190 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 29 | 0.190 |
Why?
|
| Dura Mater | 1 | 2020 | 44 | 0.180 |
Why?
|
| Consensus | 2 | 2013 | 335 | 0.180 |
Why?
|
| Benzamides | 1 | 2021 | 229 | 0.180 |
Why?
|
| Executive Function | 2 | 2019 | 86 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 166 | 0.180 |
Why?
|
| Neurofibromin 1 | 2 | 2015 | 8 | 0.180 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 147 | 0.170 |
Why?
|
| Ammonia | 3 | 1995 | 37 | 0.160 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 1998 | 28 | 0.160 |
Why?
|
| Mitochondria, Liver | 2 | 1989 | 27 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 132 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 311 | 0.150 |
Why?
|
| Carnitine | 2 | 1993 | 14 | 0.140 |
Why?
|
| Humans | 37 | 2023 | 86643 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 589 | 0.140 |
Why?
|
| Gene Deletion | 1 | 1997 | 329 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 1998 | 320 | 0.140 |
Why?
|
| Infant | 9 | 2020 | 3046 | 0.140 |
Why?
|
| Noonan Syndrome | 1 | 2015 | 5 | 0.140 |
Why?
|
| Disability Evaluation | 1 | 2016 | 136 | 0.140 |
Why?
|
| Oxidation-Reduction | 6 | 1998 | 373 | 0.140 |
Why?
|
| Brain | 3 | 1998 | 2216 | 0.130 |
Why?
|
| Receptors, Serotonin | 1 | 1995 | 34 | 0.130 |
Why?
|
| Male | 22 | 2021 | 40965 | 0.130 |
Why?
|
| Codon | 1 | 2015 | 124 | 0.130 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 2 | 1993 | 6 | 0.130 |
Why?
|
| Lipid Metabolism, Inborn Errors | 2 | 1993 | 8 | 0.130 |
Why?
|
| Liver | 4 | 1998 | 1230 | 0.130 |
Why?
|
| Phenotype | 3 | 2015 | 2378 | 0.130 |
Why?
|
| Young Adult | 7 | 2023 | 5976 | 0.130 |
Why?
|
| Spinal Neoplasms | 1 | 2014 | 50 | 0.120 |
Why?
|
| Adult | 13 | 2023 | 25648 | 0.120 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 339 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2015 | 276 | 0.120 |
Why?
|
| Valproic Acid | 1 | 1993 | 24 | 0.120 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 1993 | 7 | 0.120 |
Why?
|
| Cognition | 2 | 2019 | 570 | 0.120 |
Why?
|
| Acrocephalosyndactylia | 1 | 1993 | 6 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1464 | 0.120 |
Why?
|
| Sirolimus | 1 | 2014 | 169 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2705 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 84 | 0.110 |
Why?
|
| Mitochondria | 3 | 1993 | 535 | 0.110 |
Why?
|
| Botulism | 1 | 1992 | 6 | 0.110 |
Why?
|
| Proteins | 1 | 1997 | 777 | 0.110 |
Why?
|
| Neuromuscular Junction | 1 | 1992 | 80 | 0.100 |
Why?
|
| Hippocampus | 1 | 1995 | 442 | 0.100 |
Why?
|
| Serum Albumin, Bovine | 1 | 1991 | 45 | 0.100 |
Why?
|
| Receptors, Drug | 1 | 1991 | 54 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2003 | 2601 | 0.100 |
Why?
|
| Decompression, Surgical | 2 | 2020 | 87 | 0.100 |
Why?
|
| Oligomycins | 1 | 1990 | 5 | 0.100 |
Why?
|
| Rutamycin | 1 | 1990 | 4 | 0.100 |
Why?
|
| Social Behavior | 1 | 2013 | 294 | 0.100 |
Why?
|
| Synaptic Transmission | 1 | 1992 | 222 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 427 | 0.090 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 19 | 0.090 |
Why?
|
| Schwann Cells | 1 | 2009 | 34 | 0.090 |
Why?
|
| Female | 16 | 2021 | 44532 | 0.090 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 24 | 0.090 |
Why?
|
| Neuropsychological Tests | 3 | 2019 | 502 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1998 | 1219 | 0.080 |
Why?
|
| Albumins | 1 | 1988 | 133 | 0.080 |
Why?
|
| Rats | 5 | 1998 | 3990 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 1993 | 763 | 0.080 |
Why?
|
| Brain Damage, Chronic | 1 | 1987 | 26 | 0.080 |
Why?
|
| Hypoxia, Brain | 1 | 1987 | 41 | 0.070 |
Why?
|
| Cafe-au-Lait Spots | 1 | 2006 | 1 | 0.070 |
Why?
|
| Middle Aged | 7 | 2020 | 25028 | 0.070 |
Why?
|
| Lactates | 2 | 1985 | 37 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 151 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2006 | 121 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2006 | 236 | 0.060 |
Why?
|
| Age Factors | 2 | 2006 | 1851 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2019 | 1823 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2023 | 7993 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 3362 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 4213 | 0.060 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2003 | 35 | 0.060 |
Why?
|
| Craniotomy | 1 | 2003 | 88 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2009 | 1565 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2013 | 124 | 0.050 |
Why?
|
| Cell Membrane | 2 | 1995 | 666 | 0.050 |
Why?
|
| Muscles | 2 | 1992 | 194 | 0.050 |
Why?
|
| Cell Line | 4 | 1995 | 2468 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 54 | 0.050 |
Why?
|
| Conservative Treatment | 1 | 2020 | 20 | 0.050 |
Why?
|
| Animals | 9 | 2009 | 26582 | 0.050 |
Why?
|
| Binding, Competitive | 2 | 1991 | 145 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2015 | 2767 | 0.050 |
Why?
|
| Arteriovenous Malformations | 1 | 2000 | 41 | 0.040 |
Why?
|
| Psychometrics | 1 | 2021 | 327 | 0.040 |
Why?
|
| Pseudarthrosis | 1 | 1999 | 5 | 0.040 |
Why?
|
| Syndrome | 2 | 1993 | 446 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3640 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2000 | 140 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 1999 | 39 | 0.040 |
Why?
|
| Intellectual Disability | 2 | 1993 | 186 | 0.040 |
Why?
|
| Cholinergic Fibers | 2 | 1990 | 23 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2000 | 249 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1990 | 493 | 0.040 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 1998 | 17 | 0.040 |
Why?
|
| Cytochrome P-450 CYP4A | 1 | 1998 | 2 | 0.040 |
Why?
|
| Abdominal Neoplasms | 1 | 1998 | 39 | 0.040 |
Why?
|
| Pelvic Neoplasms | 1 | 1998 | 45 | 0.040 |
Why?
|
| Fatty Acids, Volatile | 1 | 1998 | 32 | 0.040 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 1989 | 70 | 0.040 |
Why?
|
| Thoracic Neoplasms | 1 | 1998 | 64 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1998 | 100 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1998 | 79 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 1998 | 68 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 5210 | 0.040 |
Why?
|
| Organ Specificity | 1 | 1998 | 258 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 1998 | 347 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1753 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 1997 | 232 | 0.030 |
Why?
|
| Dwarfism | 1 | 2015 | 16 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 378 | 0.030 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1995 | 3 | 0.030 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1995 | 15 | 0.030 |
Why?
|
| Tritium | 1 | 1995 | 133 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1961 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1863 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1995 | 72 | 0.030 |
Why?
|
| Acetates | 1 | 1995 | 66 | 0.030 |
Why?
|
| Exotropia | 1 | 1993 | 2 | 0.030 |
Why?
|
| Breath Tests | 1 | 1993 | 55 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 1993 | 33 | 0.030 |
Why?
|
| Thalamus | 1 | 1995 | 132 | 0.030 |
Why?
|
| Keto Acids | 1 | 1993 | 6 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 391 | 0.030 |
Why?
|
| Incidence | 1 | 1998 | 1577 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 294 | 0.030 |
Why?
|
| Hamartoma | 1 | 1993 | 31 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 1993 | 93 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 1991 | 503 | 0.030 |
Why?
|
| Learning | 1 | 2016 | 280 | 0.030 |
Why?
|
| Hybrid Cells | 2 | 1990 | 72 | 0.030 |
Why?
|
| NIMA-Related Kinases | 1 | 2013 | 7 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1718 | 0.030 |
Why?
|
| Cerebral Ventricles | 1 | 1993 | 76 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 1993 | 118 | 0.030 |
Why?
|
| Atrophy | 1 | 1993 | 117 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1993 | 315 | 0.030 |
Why?
|
| Retinal Diseases | 1 | 1993 | 90 | 0.030 |
Why?
|
| Motor Endplate | 1 | 1992 | 31 | 0.030 |
Why?
|
| Botulinum Toxins | 1 | 1992 | 17 | 0.030 |
Why?
|
| Synaptic Vesicles | 1 | 1992 | 32 | 0.030 |
Why?
|
| Attention | 1 | 2016 | 388 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1995 | 373 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2000 | 1268 | 0.030 |
Why?
|
| Family | 1 | 2013 | 311 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 3679 | 0.030 |
Why?
|
| Laurates | 1 | 1991 | 2 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1204 | 0.030 |
Why?
|
| Electromyography | 1 | 1992 | 183 | 0.030 |
Why?
|
| Acylation | 1 | 1991 | 38 | 0.030 |
Why?
|
| Palmitates | 1 | 1991 | 18 | 0.020 |
Why?
|
| Cerebellum | 1 | 1993 | 247 | 0.020 |
Why?
|
| Progesterone | 1 | 1991 | 110 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 1991 | 69 | 0.020 |
Why?
|
| Rotenone | 1 | 1990 | 17 | 0.020 |
Why?
|
| NADH Dehydrogenase | 1 | 1990 | 22 | 0.020 |
Why?
|
| Gene Expression | 1 | 1995 | 1284 | 0.020 |
Why?
|
| Septal Nuclei | 1 | 1990 | 9 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 1135 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 388 | 0.020 |
Why?
|
| Auditory Brain Stem Implants | 1 | 2009 | 1 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 1990 | 183 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 1990 | 153 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1990 | 256 | 0.020 |
Why?
|
| Cochlear Implants | 1 | 2009 | 33 | 0.020 |
Why?
|
| Epilepsy | 1 | 1993 | 397 | 0.020 |
Why?
|
| Dinitrophenols | 1 | 1989 | 7 | 0.020 |
Why?
|
| Uncoupling Agents | 1 | 1989 | 15 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 104 | 0.020 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1989 | 13 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 1989 | 49 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1995 | 1981 | 0.020 |
Why?
|
| Meningeal Neoplasms | 1 | 2009 | 61 | 0.020 |
Why?
|
| Meningioma | 1 | 2009 | 60 | 0.020 |
Why?
|
| Oleic Acid | 1 | 1988 | 14 | 0.020 |
Why?
|
| Cell Division | 1 | 1990 | 696 | 0.020 |
Why?
|
| Oleic Acids | 1 | 1988 | 26 | 0.020 |
Why?
|
| United States | 1 | 2021 | 6672 | 0.020 |
Why?
|
| Myocardium | 1 | 1991 | 529 | 0.020 |
Why?
|
| Biopsy | 1 | 1992 | 1163 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1384 | 0.020 |
Why?
|
| Intelligence | 1 | 1987 | 71 | 0.020 |
Why?
|
| Models, Molecular | 1 | 1991 | 1286 | 0.020 |
Why?
|
| Kinetics | 1 | 1988 | 1513 | 0.020 |
Why?
|
| Chinchilla | 1 | 1985 | 4 | 0.020 |
Why?
|
| Chromatography, Gas | 1 | 1985 | 28 | 0.020 |
Why?
|
| Ketone Bodies | 1 | 1985 | 17 | 0.020 |
Why?
|
| Mental Recall | 1 | 1987 | 159 | 0.020 |
Why?
|
| Uric Acid | 1 | 1985 | 139 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 1985 | 188 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1985 | 239 | 0.020 |
Why?
|
| Creatinine | 1 | 1985 | 338 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1458 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 18415 | 0.010 |
Why?
|
| Pyruvates | 1 | 1982 | 11 | 0.010 |
Why?
|
| Pyruvate Carboxylase | 1 | 1982 | 6 | 0.010 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 1982 | 13 | 0.010 |
Why?
|
| Acidosis | 1 | 1982 | 55 | 0.010 |
Why?
|
| Coma | 1 | 1982 | 44 | 0.010 |
Why?
|
| Mice | 3 | 1990 | 11352 | 0.010 |
Why?
|
| Hypesthesia | 1 | 2000 | 15 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2000 | 25 | 0.010 |
Why?
|
| Scoliosis | 1 | 2000 | 31 | 0.010 |
Why?
|
| Back Pain | 1 | 2000 | 42 | 0.010 |
Why?
|
| Foot | 1 | 2000 | 50 | 0.010 |
Why?
|
| Bone Diseases, Developmental | 1 | 1999 | 11 | 0.010 |
Why?
|
| Mutation | 1 | 1990 | 3968 | 0.010 |
Why?
|
| Choline O-Acetyltransferase | 2 | 1990 | 23 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1999 | 193 | 0.010 |
Why?
|
| Neurons | 1 | 1986 | 1546 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1982 | 873 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1565 | 0.010 |
Why?
|
| Databases, Factual | 1 | 1999 | 814 | 0.010 |
Why?
|
| Neuroblastoma | 2 | 1990 | 374 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1805 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 1052 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 312 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1990 | 3092 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1999 | 2501 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1990 | 39 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 1990 | 63 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 989 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 1990 | 207 | 0.010 |
Why?
|
| Clone Cells | 1 | 1986 | 213 | 0.000 |
Why?
|